Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Progression free survival (PFS) Description: PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by Investigator. Time frame: Up to approximately 2 years Measure: Overall survival (OS) Description: OS is defined as the time from randomization until death from any cause. Time frame: Up to approximately 2 years. After: Measure: Progression free survival (PFS) as assessed by blinded independent central review (BICR) Description: Comparison of PFS of daraxonrasib + gemcitabine and nab-paclitaxel (Arm B) versus gemcitabine and nab-paclitaxel (Arm C). PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by BICR. Time frame: Up to approximately 2 years Measure: Overall survival (OS) Description: Comparison of OS of daraxonrasib + gemcitabine and nab-paclitaxel (Arm B) versus gemcitabine and nab-paclitaxel (Arm C). OS is defined as the time from randomization until death from any cause. Time frame: Up to approximately 2 years.
Primary completion date changed
Before: Jun 2028. After: Apr 2028.